沙库巴曲缬沙坦对高血压及肾损害的研究进展
Research Progress on the Effects of Sacubitril Valsartan Sodium on Hypertension and Renal Damage
DOI: 10.12677/ACM.2023.1351188, PDF,   
作者: 张亚杰：青海大学研究生院，青海 西宁；苏晓灵*：青海省人民医院心血管内科，青海 西宁
关键词: 沙库巴曲缬沙坦；高血压；肾损害；Sacubitril Valsartan Sodium； Hypertension； Kidney Damage
摘要: 高血压是临床上最常见的心血管疾病，是导致心脑肾等靶器官损伤常见因素，而沙库巴曲缬沙坦对于高血压所致心脑肾靶器官具有保护作用，本文就高血压致肾损害机制、沙库巴曲缬沙坦对肾损害机制及临床应用作一综述。
Abstract: Hypertension is the most common cardiovascular disease in clinical practice, which is a common factor leading to damage to target organs such as cardio-cerebral kidney, and sacubitril valsartan sodium has a protective effect on cardio-cerebral renal target organs caused by hypertension. This article reviews the mechanism of kidney damage caused by hypertension, the mechanism of kidney damage caused by sacubitril valsartan sodium and its clinical application.
文章引用：张亚杰, 苏晓灵. 沙库巴曲缬沙坦对高血压及肾损害的研究进展[J]. 临床医学进展, 2023, 13(5): 8488-8492. https://doi.org/10.12677/ACM.2023.1351188

参考文献

[1] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
[2] Collins, A.J., Foley, R.N., Chavers, B., et al. (2012) United States Renal Data System 2011 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. American Journal of Kidney Diseases, 59, e1-e420.
[3] 卢辉耀, 徐训发, 郭佳音, 等. 沙库巴曲缬沙坦对心肌梗死大鼠模型心肌重构和心功能的影响[J]. 中华老年医学杂志, 2019, 38(9): 1048-1052. [Google Scholar] [CrossRef] 
[4] 高秀林. 高血压肾损害发病机制的研究进展[J]. 北京医学, 2007, 29(9): 559-561. [Google Scholar] [CrossRef] 
[5] Queisser, N., Oteiza, P.I., Stopper, H., Oli, R.G. and Schupp, N. (2011) Aldosterone Induces Oxidative Stress, Oxidative DNA Damage and NF-κB-Activation in Kidney Tubule Cells. Molecular Carcinogenesis, 50, 123-135. [Google Scholar] [CrossRef] [PubMed]
[6] Kawarazaki, H., Ando, K., Shibata, S., et al. (2012) Mineralocorticoid Re-ceptor—Racl Activation and Oxidative Stress Play Major Roles in Salt-Induced Hypertension and Kidney Injury in Pre-pubertal Rats. Journal of Hypertension, 30, 1977-1985. [Google Scholar] [CrossRef] 
[7] Kawarazaki, W., Nagase, M., Yoshida, S., et al. (2012) An-giotensin II- and Salt-Induced Kidney Injury through Rac1-Mediated Mineralocorticoid Receptor Activation. Journal of the American Society of Nephrology, 23, 997-1007. [Google Scholar] [CrossRef] 
[8] Wang, G., Lai, F.M., Kwan, B.C., et al. (2009) Podocyte Loss in Human Hypertensive Nephrosclerosis. American Journal of Hypertension, 22, 300-306. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, S.M., Kim, Y.G., Jeong, K.H., et al. (2012) Angiotensin II-Induced Mitochondrial Nox4 Is a Major Endogenous Source of Oxidative Stress in Kidney Tubular Cells. PLOS ONE, 7, e39739. [Google Scholar] [CrossRef] [PubMed]
[10] Shankar, A., Li, J., Nieto, F.J., Klein, B.E.K. and Klein, R. (2007) Association between C-Reactive Protein Level and Peripheral Arterial Disease among US Adults without Cardio-vascular Disease, Diabetes, or Hypertension. American Heart Journal, 154, 495-501. [Google Scholar] [CrossRef] [PubMed]
[11] Okamura, A., Rakugi, H., Ohishi, M., et al. (1999) Upregulation of Renin-Angiotensin System during Differentiation of Monocytes to Macrophages. Journal of Hypertension, 17, 537-545. [Google Scholar] [CrossRef] [PubMed]
[12] Diet, F., Pratt, R.E., Berry, G.J., Momose, N., Gibbons, G.H. and Dzau, V.J. (1996) Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease. Circulation, 94, 2756-2767. [Google Scholar] [CrossRef] 
[13] Xia, Y., Entman, M.L. and Wang, Y. (2013) Critical Role of CXCL16 in Hypertensive Kidney Injury and Fibrosis. Hypertension, 62, 1129-1137. [Google Scholar] [CrossRef] 
[14] Xia, Y., Jin, X., Yan, J., et al. (2014) CXCR6 Plays a Critical Role in Angiotensin II-Induced Renal Injury and Fibrosis. Arteriosclerosis, Thrombosis and Vascular Biology, 34, 1422-1428. [Google Scholar] [CrossRef] 
[15] Endlich, N. and Endlich, K. (2012) The Challenge and Response of Podocytes to Glomerular Hypertension. Seminars in Nephrology, 32, 327-341. [Google Scholar] [CrossRef] [PubMed]
[16] Shi, J., Wang, X., Nguyen, J., et al. (2016) Sacubitril Is Se-lectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metabolism and Disposition, 44, 554-559. [Google Scholar] [CrossRef] [PubMed]
[17] Andersen, M.B., Simonsen, U., Wehland, M., et al. (2016) LCZ696 (Valsartan/Sacubitril)—A Possible New Treatment for Hypertension and Heart Failure. Basic & Clinical Pharmacology & Toxicology, 118, 14-22. [Google Scholar] [CrossRef] [PubMed]
[18] Zietse, R. (2005) Atrial Natriuretic Peptide: A Regulator of Transvascular Fluid Transport in Dialysis? Blood Purification, 23, 429-430. [Google Scholar] [CrossRef] [PubMed]
[19] Esser, N. and Zraika, S. (2019) Neprilysin Inhibition: A New Therapeutic Option for Type 2 Diabetes? Diabetologia, 62, 1113-1122. [Google Scholar] [CrossRef] [PubMed]
[20] Packer, M. (2018) Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes. Diabetes, Obesity and Metabolism, 20, 800-811. [Google Scholar] [CrossRef] [PubMed]
[21] Procopio, P.R., Gaubeur, M.A., Itezerote, A.M., et al. (2020) Anatomical Study of the Innervation of the Masseter Muscle and Its Correlation with Myofascial Trigger Points. Journal of Pain Re-search, 13, 3217-3226. [Google Scholar] [CrossRef] 
[22] Lin, L.M., Wu, Y., Wu, M.F., et al. (2016) Focus on the Novel Cardio-vascular Drug LZC696: from Evidence to Clinical Consideration. Cardiovascular Drugs and Therapy, 30, 623-633. [Google Scholar] [CrossRef] [PubMed]
[23] Uijl, E., Roksnoer L, et al. (2020) Angiotensin-Neprilysin Inhibi-tion Confers Renoprotection in Rats with Diabetes and Hypertension by Limiting Podocyte Injury. Journal of Hyperten-sion, 38, 755-764. [Google Scholar] [CrossRef] 
[24] Unger, T., Borghi, C., Charchar, F., et al. (2020) 2020 In-ternational Society of Hypertension Global Hypertension Practice Guidelines. Journal of Hypertension, 38, 982-1004. [Google Scholar] [CrossRef] 
[25] 中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2): 108-114.

为你推荐